BNP Paribas boosted its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 15.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 91,694 shares of the company’s stock after purchasing an additional 12,098 shares during the quarter. BNP Paribas’ holdings in AbbVie were worth $24,025,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Verus Financial Partners Inc. increased its position in shares of AbbVie by 1.7% during the third quarter. Verus Financial Partners Inc. now owns 2,048 shares of the company’s stock valued at $536,000 after purchasing an additional 35 shares during the period. Evergreen Private Wealth LLC lifted its position in AbbVie by 3.3% in the third quarter. Evergreen Private Wealth LLC now owns 1,090 shares of the company’s stock worth $285,000 after purchasing an additional 35 shares during the period. Lifelong Wealth Advisors Inc. lifted its position in AbbVie by 2.1% in the third quarter. Lifelong Wealth Advisors Inc. now owns 1,755 shares of the company’s stock worth $459,000 after purchasing an additional 36 shares during the period. IMG Wealth Management Inc. boosted its stake in AbbVie by 22.8% during the third quarter. IMG Wealth Management Inc. now owns 194 shares of the company’s stock worth $51,000 after buying an additional 36 shares in the last quarter. Finally, Foundry Financial Group Inc. boosted its stake in AbbVie by 4.6% during the third quarter. Foundry Financial Group Inc. now owns 839 shares of the company’s stock worth $219,000 after buying an additional 37 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at AbbVie
In other news, EVP Jeffrey Stewart sold 40,619 shares of the business’s stock in a transaction on Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the completion of the transaction, the executive vice president owned 83,171 shares of the company’s stock, valued at $24,419,005.60. The trade was a 32.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is currently owned by corporate insiders.
AbbVie Trading Up 0.9%
AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The company had revenue of $17.40 billion during the quarter, compared to analysts’ expectations of $17.32 billion. During the same period in the prior year, the business posted $1.86 EPS. AbbVie’s revenue was up 10.3% on a year-over-year basis. As a group, equities analysts forecast that AbbVie Inc. will post 13.99 EPS for the current year.
AbbVie Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be given a dividend of $1.82 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Friday, January 15th. AbbVie’s payout ratio is 119.10%.
Wall Street Analysts Forecast Growth
ABBV has been the subject of a number of recent research reports. Royal Bank Of Canada increased their price objective on shares of AbbVie from $280.00 to $330.00 and gave the company an “outperform” rating in a research note on Monday, November 2nd. The Goldman Sachs Group boosted their price objective on AbbVie from $258.00 to $294.00 and gave the stock a “neutral” rating in a research note on Friday, October 23rd. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. BNP Paribas Exane lifted their price target on shares of AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Finally, Sanford C. Bernstein restated a “market perform” rating and issued a $275.00 price objective on shares of AbbVie in a report on Monday, November 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $299.62.
Check Out Our Latest Research Report on AbbVie
Key Stories Impacting AbbVie
Here are a few of the latest stories about ABBV:
- Positive Sentiment: Piper Sandler raised its price target to $349 from $303 and maintained an Overweight rating, implying about 23% upside from the prior close. Article: AbbVie Is Near Its High. Piper Sandler Sees Another 23%
- Positive Sentiment: AbbVie partnered with DISCO Pharmaceuticals to discover next-generation bispecific cancer therapies for solid tumors. DISCO could receive up to $2.5 billion in milestone payments, while AbbVie has options to license selected programs; the deal adds pipeline potential, though returns depend on successful research and development. Article: DISCO, AbbVie Sign AND-Gated Bispecific Deal Worth Up to $2.5B
- Neutral Sentiment: AbbVie will present at the Piper Sandler healthcare conference on December 2; the announcement may provide an opportunity for updates but includes no new business guidance. Article: AbbVie to Present at the Piper Sandler 38th Annual Healthcare Conference
About AbbVie
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Featured Stories
- Five stocks we like better than AbbVie
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
